Hepatitis C: Is eradication possible?
Antiviral Agents
/ adverse effects
Delivery of Health Care, Integrated
/ organization & administration
Disease Eradication
Global Health
Health Services Accessibility
/ organization & administration
Hepacivirus
/ drug effects
Hepatitis C
/ diagnosis
Humans
Prevalence
Risk Factors
Time Factors
Treatment Outcome
Viral Hepatitis Vaccines
/ adverse effects
DAA
HCV
HCV-vaccine
linkage to care
viral eradication
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
22
09
2018
revised:
06
11
2018
accepted:
19
11
2018
pubmed:
26
11
2018
medline:
14
4
2020
entrez:
26
11
2018
Statut:
ppublish
Résumé
Hepatitis C has a relevant global impact in terms of morbidity, mortality and economic costs, with more than 70 million people infected worldwide. In the resolution, "Transforming our world: the 2030 Agenda for Sustainable Development" was included as a focus area in the health-related goal with world leaders pledging to "combat" it by 2030. In response, WHO drafted the Global Viral Hepatitis Strategy carrying the ambitious targets to reduce the number of deaths by two-thirds and to increase treatment rates up to 80%. Despite the availability of highly effective therapeutic regimens based on direct-acting antivirals many barriers to HCV eradication still remain. They are related to awareness of the infection, linkage to care, availability of the therapeutic drug regimens and reinfection. Overall, if an effective prophylactic vaccine will not be available, HCV eradication appears difficult to achieve in the future.
Substances chimiques
Antiviral Agents
0
Viral Hepatitis Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
416-426Informations de copyright
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.